Company Filing History:
6 out of 4,945 
1 out of 46 
Years Active: 2018-2025
Title: Christoph Patsch: Innovator in Oligonucleotide Technology
Introduction
Christoph Patsch is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotides for therapeutic applications. With a total of seven patents to his name, Patsch is recognized for his innovative approaches to complex biological challenges.
Latest Patents
One of Christoph Patsch's latest patents focuses on oligonucleotides that induce paternal UBE3A expression. This invention relates to oligonucleotides capable of inducing the expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridizing to SNHG14 long non-coding RNA downstream of SNORD1091B. This invention also encompasses pharmaceutical compositions and methods for treating Angelman syndrome.
Career Highlights
Throughout his career, Christoph Patsch has worked with prominent companies in the biotechnology sector. He has been associated with Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. His work in these organizations has allowed him to advance his research and contribute to significant innovations in the field.
Collaborations
Christoph Patsch has collaborated with several professionals in his field, including Veronica Costa and Maj Hedtjärn. These collaborations have enriched his research and have led to the development of impactful inventions.
Conclusion
Christoph Patsch is a distinguished inventor whose work in oligonucleotide technology has the potential to transform therapeutic approaches for genetic disorders. His contributions to the field are marked by a commitment to innovation and collaboration.